Unexpected regulatory role of CCR9 in regulatory T cell development

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Evans Marin, Heather L ^a   Cao, Anthony T ^a   Yao, Suxia ^a   Chen, Feidi ^a   He, Chong ^a,b   Liu, Han ^a,c   Wu, Wei ^a,b   Gonzalez, Maria G ^a   Dann, Sara M ^d   Cong, Yingzi ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b TONGJI UNIVERSITY   (China)

^c SHANDONG UNIVERSITY   (China)

^d UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR9; LIGAND; TRANSCRIPTION FACTOR FOXP3; CC CHEMOKINE RECEPTOR 9; CHEMOKINE RECEPTOR CCR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CELL HOMING; CELL MATURATION; COLITIS; CONTROLLED STUDY; EFFECTOR CELL; FOXP3+ REGULATORY T LYMPHOCYTE; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; IMMUNOREGULATION; IN VITRO STUDY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T LYMPHOCYTE; ANIMAL; CYTOLOGY; GENETICS; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; COLITIS; MICE; MICE, TRANSGENIC; RECEPTORS, CCR; T-LYMPHOCYTES, REGULATORY;

EID: 84941975885     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0134100     Document Type: Article

References (36)

1. Baumgart DC. The diagnosis and treatment of Crohn's disease and ulcerative colitis. Dtsch Arztebl Int [Internet]. 2009 Feb. [cited 2015 Jan 23]; 106(8):123-33. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2695363&tool = pmcentrez&rendertype = abstract.
2. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest [Internet]. 2007 Mar. [cited 2015 Jan 21]; 117(3):514-21. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1804356&tool = pmcentrez&rendertype = abstract.
3. Elson CO, Cong Y. Host-microbiota interactions in inflammatory bowel disease. Gut Microbes [Internet]. Jan [cited 2015 Jan 23]; 3(4):332-44. Available: http://www.pubmedcentral.nih.gov/articlerender. fcgi?artid=3463491&tool = pmcentrez&rendertype = abstract.
4. Evans-Marin HL, Cong Y. Microbiota regulation of inflammatory bowel disease. Inflamm Allergy Drug Targets [Internet]. 2014 Feb. [cited 2015 Jan 23]; 13(1):65-73. Available: http://www.ncbi.nlm.nih.gov/pubmed/24438006.
5. Neurath MF, Fuss I, Kelsall BL, Stüber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med [Internet]. 1995 Nov. 1 [cited 2015 Mar. 17]; 182(5):1281-90. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2192205&tool = pmcentrez&rendertype = abstract.
6. Feng T, Qin H, Wang L, Benveniste EN, Elson CO, Cong Y. Th17 cells induce colitis and promote Th1 cell responses through IL-17 induction of innate IL-12 and IL-23 production. J Immunol [Internet]. 2011 Jun. 1 [cited 2015 Jan 7]; 186(11):6313-8. Available: http://www.pubmedcentral.nih.gov/articlerender. fcgi?artid=3249225&tool = pmcentrez&rendertype = abstract.
7. Shale M, Schiering C, Powrie F. CD4(+) T-cell subsets in intestinal inflammation. Immunol Rev [Internet]. 2013 Mar. [cited 2015 Mar. 11]; 252(1):164-82. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3736165&tool = pmcentrez&rendertype = abstract.
8. Buckner JH. Mechanisms of impaired regulation by CD4(+) CD25 (+) FOXP3 (+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol [Internet]. 2010 Dec. [cited 2014 Dec. 3]; 10(12):849-59. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3046807&tool = pmcentrez&rendertype = abstract.
9. Monteleone G, Boirivant M, Pallone F, MacDonald TT. TGF-beta1 and Smad7 in the regulation of IBD. Mucosal Immunol [Internet]. Society for Mucosal Immunology Ltd; 2008 Nov. [cited 2015 Feb. 9]; 1 Suppl 1(1s:):S50-3. Available: doi: 10.1038/mi.2008.55
10. Schmidt A, Oberle N, Krammer PH. Molecular mechanisms of treg-mediated T cell suppression. Front Immunol [Internet]. 2012 Jan [cited 2014 Dec. 11]; 3:51. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3341960&tool = pmcentrez&rendertype = abstract.
11. Danese S, Panés J. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases. Gastroenterology [Internet]. Elsevier; 2014 Nov. 11 [cited 2015 Jan 20]; 147(5):981-9. Available: http://www.gastrojournal.org/article/S0016508514010877/fulltext.
12. Rivera-Nieves J, Ho J, Bamias G, Ivashkina N, Ley K, Oppermann M, et al. Antibody blockade of CCL25/CCR9 ameliorates early but not late chronic murine ileitis. Gastroenterology [Internet]. 2006 Nov. [cited 2015 Jan 23]; 131(5):1518-29. Available: http://www.ncbi.nlm.nih.gov/pubmed/17101325.
13. Cassani B, Villablanca EJ, Quintana FJ, Love PE, Lacy-Hulbert A, Blaner WS, et al. Gut-tropic T cells that express integrin α4β7 and CCR9 are required for induction of oral immune tolerance in mice. Gastroenterology [Internet]. 2011 Dec. [cited 2014 Dec. 30]; 141(6):2109-18. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3222333&tool = pmcentrez&rendertype = abstract.
14. Uehara S, Grinberg A, Farber JM, Love PE. A role for CCR9 in T lymphocyte development and migration. J Immunol [Internet]. 2002 Mar. 15 [cited 2015 Jan 23]; 168(6):2811-9. Available: http://www.ncbi. nlm.nih.gov/pubmed/11884450.
15. Wermers JD, McNamee EN, Wurbel M-A, Jedlicka P, Rivera-Nieves J. The chemokine receptor CCR9 is required for the T-cell-mediated regulation of chronic ileitis in mice. Gastroenterology [Internet]. 2011 May [cited 2015 Jan 23]; 140(5):1526-35.e3. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3086928&tool = pmcentrez&rendertype = abstract.
16. Keshav S, Vaòásek T, Niv Y, Petryka R, Howaldt S, Bafutto M, et al. A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease. PLoS One [Internet]. 2013 Jan [cited 2015 Jan 23]; 8(3):e60094. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3603920&tool = pmcentrez&rendertype = abstract.
17. Walters MJ, Wang Y, Lai N, Baumgart T, Zhao BN, Dairaghi DJ, et al. Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. J Pharmacol Exp Ther [Internet]. 2010 Oct. [cited 2015 Jan 23]; 335(1):61-9. Available: http://www.ncbi.nlm.nih.gov/pubmed/20660125.
18. Hosoe N, Miura S, Watanabe C, Tsuzuki Y, Hokari R, Oyama T, et al. Demonstration of functional role of TECK/CCL25 in T lymphocyte-endothelium interaction in inflamed and uninflamed intestinal mucosa. Am J Physiol Gastrointest Liver Physiol [Internet]. 2004 Mar. [cited 2015 Jan 23]; 286(3):G458-66. Available: http://www.ncbi.nlm.nih.gov/pubmed/14592943.
19. Saruta M, Yu QT, Avanesyan A, Fleshner PR, Targan SR, Papadakis KA. Phenotype and effector function of CC chemokine receptor 9-expressing lymphocytes in small intestinal Crohn's disease. J Immunol [Internet]. 2007 Mar. 1 [cited 2015 Jan 23]; 178(5):3293-300. Available: http://www.ncbi.nlm.nih. gov/pubmed/17312180.
20. Eberhardson M, Marits P, Jones M, Jones P, Karlen P, Karlsson M, et al. Treatment of inflammatory bowel disease by chemokine receptor-targeted leukapheresis. Clin Immunol [Internet]. 2013 Oct. [cited 2015 Jan 23]; 149(1):73-82. Available: http://www.ncbi.nlm.nih.gov/pubmed/23892544.
21. Villablanca EJ, Cassani B, von Andrian UH, Mora JR. Blocking lymphocyte localization to the gastrointestinal mucosa as a therapeutic strategy for inflammatory bowel diseases. Gastroenterology [Internet]. 2011 May [cited 2015 Jan 23]; 140(6):1776-84. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3102304&tool = pmcentrez&rendertype = abstract.
22. Wurbel M-A, McIntire MG, Dwyer P, Fiebiger E. CCL25/CCR9 interactions regulate large intestinal inflammation in a murine model of acute colitis. PLoS One [Internet]. 2011 Jan [cited 2015 Jan 23]; 6(1):e16442. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3026821&tool = pmcentrez&rendertype = abstract.
23. Johnson EL, Singh R, Johnson-Holiday CM, Grizzle WE, Partridge EE, Lillard JW, et al. CCR9 interactions support ovarian cancer cell survival and resistance to cisplatin-induced apoptosis in a PI3Kdependent and FAK-independent fashion. J Ovarian Res [Internet]. 2010 Jan [cited 2015 Jan 23]; 3:15. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2914045&tool = pmcentrez&rendertype = abstract.
24. Sharma PK, Singh R, Novakovic KR, Eaton JW, Grizzle WE, Singh S. CCR9 mediates PI3K/AKTdependent antiapoptotic signals in prostate cancer cells and inhibition of CCR9-CCL25 interaction enhances the cytotoxic effects of etoposide. Int J Cancer [Internet]. 2010 Nov. 1 [cited 2015 Jan 23]; 127(9):2020-30. Available: http://www.ncbi.nlm.nih.gov/pubmed/20127861.
25. Meiron M, Zohar Y, Anunu R, Wildbaum G, Karin N. CXCL12(SDF-1alpha) suppresses ongoing experimental autoimmune encephalomyelitis by selecting antigen-specific regulatory T cells. J Exp Med [Internet]. 2008 Oct. 27 [cited 2015 Jan 12]; 205(11):2643-55. Available: http://jem.rupress.org/content/205/11/2643.long.
26. Zohar Y, Wildbaum G, Novak R, Salzman AL, Thelen M, Alon R, et al. CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis. J Clin Invest [Internet]. American Society for Clinical Investigation; 2014 May 1 [cited 2015 Feb. 5]; 124(5):2009-22. Available: http://www.jci.org/articles/view/71951.
27. Shachar I, Karin N. The dual roles of inflammatory cytokines and chemokines in the regulation of autoimmune diseases and their clinical implications. J Leukoc Biol [Internet]. 2013 Jan 1 [cited 2015 Feb. 5]; 93(1):51-61. Available: http://www.jleukbio.org/content/93/1/51.long.
28. Karin N. The multiple faces of CXCL12(SDF-1alpha) in the regulation of immunity during health and disease. J Leukoc Biol [Internet]. 2010 Sep. 1 [cited 2015 Feb. 5]; 88(3):463-73. Available: http://www.jleukbio.org/content/88/3/463.long.
29. Sapir Y, Vitenshtein A, Barsheshet Y, Zohar Y, Wildbaum G, Karin N. A fusion protein encoding the second extracellular domain of CCR5 arrests chemokine-induced cosignaling and effectively suppresses ongoing experimental autoimmune encephalomyelitis. J Immunol [Internet]. American Association of Immunologists; 2010 Aug. 15 [cited 2015 Feb. 5]; 185(4):2589-99. Available: http://www.jimmunol.org/content/185/4/2589.full.
30. Feng T, Wang L, Schoeb TR, Elson CO, Cong Y. Microbiota innate stimulation is a prerequisite for T cell spontaneous proliferation and induction of experimental colitis. J Exp Med [Internet]. 2010 Jun. 7 [cited 2015 Jan 23]; 207(6):1321-32. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi? artid=2882839&tool = pmcentrez&rendertype = abstract.
31. Wurbel M-A, Le Bras S, Ibourk M, Pardo M, McIntire MG, Coco D, et al. CCL25/CCR9 interactions are not essential for colitis development but are required for innate immune cell protection from chronic experimental murine colitis. Inflamm Bowel Dis [Internet]. 2014 Jul. [cited 2015 Feb. 9]; 20(7):1165-76. Available: http://www.ncbi.nlm.nih.gov/pubmed/24874458.
32. Hart AL, Ng SC, Mann E, Al-Hassi HO, Bernardo D, Knight SC. Homing of immune cells: role in homeostasis and intestinal inflammation. Inflamm Bowel Dis [Internet]. 2010 Nov. [cited 2015 Jan 26]; 16(11):1969-77. Available: http://www.ncbi.nlm.nih.gov/pubmed/20848507.
33. Ohoka Y, Yokota A, Takeuchi H, Maeda N, Iwata M. Retinoic acid-induced CCR9 expression requires transient TCR stimulation and cooperativity between NFATc2 and the retinoic acid receptor/retinoid X receptor complex. J Immunol [Internet]. American Association of Immunologists; 2011 Jan 15 [cited 2015 May 27]; 186(2):733-44. Available: http://www.jimmunol.org/content/186/2/733.full.
34. Linton L, Karlsson M, Grundström J, Hjalmarsson E, Lindberg A, Lindh E, et al. HLA-DR (hi) and CCR9 Define a Pro-Inflammatory Monocyte Subset in IBD. Clin Transl Gastroenterol [Internet]. 2012 Jan [cited 2015 Jan 23]; 3:e29. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid= 3535076&tool = pmcentrez&rendertype = abstract.
35. Karlsson F, Martinez NE, Gray L, Zhang S, Tsunoda I, Grisham MB. Therapeutic evaluation of ex vivogenerated versus natural regulatory T-cells in a mouse model of chronic gut inflammation. Inflamm Bowel Dis [Internet]. 2013 Oct. [cited 2015 Mar. 17]; 19(11):2282-94. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3812251&tool = pmcentrez&rendertype = abstract.
36. Nanki T, Lipsky PE. Cutting edge: stromal cell-derived factor-1 is a costimulator for CD4+ T cell activation. J Immunol [Internet]. 2000 May 15 [cited 2015 Mar. 17]; 164(10):5010-4. Available: http://www.ncbi.nlm.nih.gov/pubmed/10799853.